PL2187882T3 - Leczenie postępującej choroby neurodegeneracyjnej ibudilastem - Google Patents

Leczenie postępującej choroby neurodegeneracyjnej ibudilastem

Info

Publication number: PL2187882T3
Authority: PL; Poland
Prior art keywords: ibudilast; treatment; neurodegenerative disease; progressive neurodegenerative; progressive
Prior art date: 2007-07-11

Application number

PL08781498T

Other languages

English (en)

Inventor

Michael E Kalafer

Kenneth W Locke

Kazuko Matsuda

Richard E Gammans

Original Assignee

Medicinova Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-11

Filing date

2008-07-08

Publication date

2013-05-31

2008-07-08 Application filed by Medicinova Inc filed Critical Medicinova Inc

2013-05-31 Publication of PL2187882T3 publication Critical patent/PL2187882T3/pl

Links

ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 title 1
229960002491 ibudilast Drugs 0.000 title 1
230000004770 neurodegeneration Effects 0.000 title 1
208000015122 neurodegenerative disease Diseases 0.000 title 1
230000000750 progressive effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL08781498T 2007-07-11 2008-07-08 Leczenie postępującej choroby neurodegeneracyjnej ibudilastem PL2187882T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US92974507P	2007-07-11	2007-07-11
US4218108P	2008-04-03	2008-04-03
PCT/US2008/069417 WO2009009529A1 (en)	2007-07-11	2008-07-08	Treatment of progressive neurodegenerative disease with ibudilast
EP08781498A EP2187882B1 (en)	2007-07-11	2008-07-08	Treatment of progressive neurodegenerative disease with ibudilast

Publications (1)

Publication Number	Publication Date
PL2187882T3 true PL2187882T3 (pl)	2013-05-31

Family

ID=39789775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08781498T PL2187882T3 (pl)	2007-07-11	2008-07-08	Leczenie postępującej choroby neurodegeneracyjnej ibudilastem

Country Status (14)

Country	Link
US (10)	US8138201B2 (pl)
EP (2)	EP2567699A1 (pl)
JP (2)	JP5468001B2 (pl)
CN (1)	CN101848712B (pl)
AU (1)	AU2008275148A1 (pl)
BR (1)	BRPI0814624A2 (pl)
CA (2)	CA2970273C (pl)
DK (1)	DK2187882T3 (pl)
ES (1)	ES2402175T3 (pl)
HR (1)	HRP20130057T1 (pl)
PL (1)	PL2187882T3 (pl)
PT (1)	PT2187882E (pl)
TW (1)	TW200918051A (pl)
WO (1)	WO2009009529A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112012000568A2 (pt) *	2009-06-19	2015-10-06	Teva Pharma	tratamento da esclerose múltipla com laquinimod
US8119657B2 (en)	2009-06-23	2012-02-21	Medicinova, Inc.	Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-α]pyridin-3-yl)propan-1-one and related methods
JP5882208B2 (ja) *	2009-07-30	2016-03-09	テバファーマシューティカルインダストリーズリミティド	ラキニモドによるクローン病の治療
AU2010282948C1 (en) *	2009-08-10	2017-03-02	Active Biotech, Ab	Treatment of BDNF-related disorders using laquinimod
DK3536333T3 (da) *	2010-01-04	2022-10-24	Mapi Pharma Ltd	Depotsystem der omfatter glatirameracetat
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN102781239B (zh) *	2010-03-03	2015-01-21	泰华制药工业有限公司	使用拉喹莫德治疗狼疮关节炎
EA201290837A1 (ru) *	2010-03-03	2013-05-30	Тева Фармасьютикал Индастриз Лтд.	Лечение волчаночного нефрита с применением лаквинимода
SI2542079T1 (sl) *	2010-03-03	2014-08-29	Teva Pharmaceutical Industries Ltd.	Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
EP2699317B1 (en)	2011-04-21	2016-08-10	Mapi Pharma Limited	Random pentapolymer for treatment of autoimmune diseases
JP2014530821A (ja)	2011-10-12	2014-11-20	テバファーマシューティカルインダストリーズリミティド	ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
WO2013116657A1 (en)	2012-02-03	2013-08-08	Teva Pharmaceutical Industries Ltd.	USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
CN103255142B (zh) *	2012-02-21	2017-07-25	上海转基因研究中心	一种利用RNAi调控内源性朊蛋白表达的方法及其应用
TW201400117A (zh)	2012-06-05	2014-01-01	Teva Pharma	使用拉喹莫德治療眼發炎疾病
CN103505731A (zh) *	2012-06-15	2014-01-15	中国药科大学	1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
FR3000746A1 (fr)	2013-01-04	2014-07-11	Centre Nat Rech Scient	Peptide pour son utilisation dans le traitement des neuronopathies motrices
HK1218254A1 (zh) *	2013-02-15	2017-02-10	Teva Pharmaceutical Industries Ltd.	用拉喹莫德治疗多发性硬化症
JP2016517883A (ja)	2013-05-03	2016-06-20	オレゴンヘルスアンドサイエンスユニバーシティー	Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
SG11201608674UA (en)	2014-04-29	2016-11-29	Teva Pharma	Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2015195822A1 (en) *	2014-06-20	2015-12-23	Medicinova, Inc.	A combination of geranylgeranylacetone and ibudilast and methods of using same
CA2961187A1 (en) *	2014-09-16	2016-03-24	Teva Pharmaceuticals Industries Ltd.	Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
KR102462638B1 (ko) *	2014-11-26	2022-11-03	메디시노바, 인크.	이부딜라스트와 릴루졸의 배합물 및 이의 사용방법
WO2016086000A1 (en) *	2014-11-26	2016-06-02	Medicinova, Inc.	A combination of geranygeranylacetone, ibudilast, and riluzole and methods of using same
CN105395511A (zh) *	2015-12-07	2016-03-16	黑龙江省智诚医药科技有限公司	一种异丁司特缓释微丸及其制备方法
ES2917618T3 (es) *	2016-05-10	2022-07-11	Medicinova Inc	Tratamiento del alcoholismo y la depresión mediante el uso de ibudilast
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en)	2016-08-31	2024-09-05	Mapi Pharma Ltd	Depot systems comprising glatiramer acetate
WO2018119262A1 (en) *	2016-12-22	2018-06-28	Medicinova, Inc.	Methods of treating glioblastoma multiforme using ibudilast
MX2019010174A (es)	2017-03-26	2019-10-15	Mapi Pharma Ltd	Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
CA3090887A1 (en) *	2018-02-12	2019-08-15	Medicinova, Inc.	Methods of suppressing myeloid-derived suppressor cells in patients
CN112236140A (zh) *	2018-02-12	2021-01-15	美迪诺亚公司	用于癌症治疗的使用异丁司特和第二药剂的方法和剂量方案
US10946071B2 (en)	2018-10-09	2021-03-16	Medicinova, Inc.	Combination of ibudilast and interferon-beta and methods of using same
US11154540B2 (en) *	2018-10-19	2021-10-26	Medicinova, Inc.	Methods of treating ophthalmic disease/disorder or injury with ibudilast
JP2022513449A (ja)	2018-12-12	2022-02-08	オートバーンセラピューティクス，インク．	新規な甲状腺模倣物
JP7580380B2 (ja) *	2019-02-26	2024-11-11	ウニベルシタットデバレンシア―エストゥディジェネラル	運動ニューロン疾患を処置するための方法及び組成物
EP3931180A1 (en)	2019-03-01	2022-01-05	Autobahn Therapeutics, Inc.	Novel thyromimetics
WO2020251748A1 (en) *	2019-06-11	2020-12-17	Yale University	Novel treatment for wolfram syndrome
EP4034090A1 (en)	2019-09-23	2022-08-03	MediciNova, Inc.	Ibudilast oral formulations and methods of using same
IL293389B1 (en)	2019-11-29	2025-12-01	Autobahn Therapeutics Inc	Novel thyromimetics
CN115335049A (zh) *	2020-04-06	2022-11-11	美迪诺亚公司	降低患者中巨噬细胞迁移抑制因子的血浆水平的方法
US12528761B2 (en)	2020-06-17	2026-01-20	Autobahn Therapeutics, Inc.	Thyromimetics
WO2022164948A1 (en)	2021-01-29	2022-08-04	Medicinova, Inc.	Methods of treating chemical gas exposure
JP2024528731A (ja)	2021-07-26	2024-07-30	メディシノバ・インコーポレイテッド	眼癌転移を予防するためのイブジラスト
US20230090534A1 (en)	2021-09-21	2023-03-23	Medicinova, Inc.	Methods of treating glioblastoma multiforme using combination therapy
US12042485B2 (en)	2021-10-07	2024-07-23	Medicinova, Inc.	Methods of minimizing cancer metastasis
US12171752B2 (en)	2022-02-01	2024-12-24	Medicinova, Inc.	Methods of treating post-COVID condition(s)
JP2025510339A (ja) *	2022-03-28	2025-04-14	プラクシスプレシジョンメディシンズ，インコーポレイテッド	オリゴマー化合物を使用してｓｃｎ２ａ関連障害を治療する方法
JP2025523822A (ja)	2022-07-13	2025-07-25	メディシノバ・インコーポレイテッド	イブジラストの注射用製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU8562198A (en)	1998-08-10	2000-03-06	Kyorin Pharmaceutical Co. Ltd.	Remedies for multiple sclerosis
CA2427430A1 (en)	2000-11-02	2002-06-13	Research Foundation Of City University Of New York	Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
US20050043319A1 (en) *	2001-08-14	2005-02-24	Exonhit Therapeutics Sa	Molecular target of neurotoxicity
KR20060120208A (ko)	2003-11-21	2006-11-24	콤비네이토릭스, 인코포레이티드	염증성 질환의 치료 방법 및 시약
WO2006063048A2 (en) *	2004-12-06	2006-06-15	Avigen, Inc.	Ibudilast for treating neuropathic pain and associated syndromes
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節

2008
- 2008-07-08 EP EP12196108A patent/EP2567699A1/en not_active Withdrawn
- 2008-07-08 BR BRPI0814624-1A2A patent/BRPI0814624A2/pt not_active Application Discontinuation
- 2008-07-08 HR HRP20130057AT patent/HRP20130057T1/hr unknown
- 2008-07-08 PL PL08781498T patent/PL2187882T3/pl unknown
- 2008-07-08 EP EP08781498A patent/EP2187882B1/en active Active
- 2008-07-08 DK DK08781498.4T patent/DK2187882T3/da active
- 2008-07-08 CA CA2970273A patent/CA2970273C/en active Active
- 2008-07-08 AU AU2008275148A patent/AU2008275148A1/en not_active Abandoned
- 2008-07-08 WO PCT/US2008/069417 patent/WO2009009529A1/en not_active Ceased
- 2008-07-08 CN CN200880106623XA patent/CN101848712B/zh active Active
- 2008-07-08 US US12/169,042 patent/US8138201B2/en active Active
- 2008-07-08 CA CA2693697A patent/CA2693697C/en active Active
- 2008-07-08 JP JP2010516198A patent/JP5468001B2/ja active Active
- 2008-07-08 PT PT87814984T patent/PT2187882E/pt unknown
- 2008-07-08 ES ES08781498T patent/ES2402175T3/es active Active
- 2008-07-10 TW TW097126065A patent/TW200918051A/zh unknown
2012
- 2012-02-22 US US13/402,702 patent/US8338453B2/en active Active
- 2012-12-21 US US13/725,627 patent/US9114136B2/en active Active
2013
- 2013-12-10 JP JP2013255214A patent/JP2014062118A/ja active Pending
2014
- 2014-02-24 US US14/188,061 patent/US9314452B2/en active Active
- 2014-09-19 US US14/491,939 patent/US20150011581A1/en not_active Abandoned
2016
- 2016-03-23 US US15/078,291 patent/US20170014390A1/en not_active Abandoned
- 2016-10-07 US US15/288,582 patent/US20170020851A1/en not_active Abandoned
2019
- 2019-05-01 US US16/400,844 patent/US11083713B2/en active Active
2021
- 2021-07-02 US US17/366,563 patent/US11944607B2/en active Active
2024
- 2024-03-29 US US18/621,850 patent/US20250073213A1/en active Pending

Also Published As

Publication number	Publication date
EP2567699A1 (en)	2013-03-13
AU2008275148A1 (en)	2009-01-15
ES2402175T3 (es)	2013-04-29
US11944607B2 (en)	2024-04-02
US20150011581A1 (en)	2015-01-08
EP2187882A1 (en)	2010-05-26
EP2187882B1 (en)	2013-01-09
US9114136B2 (en)	2015-08-25
US20120214839A1 (en)	2012-08-23
US8138201B2 (en)	2012-03-20
WO2009009529A1 (en)	2009-01-15
CA2970273C (en)	2020-04-14
TW200918051A (en)	2009-05-01
US20250073213A1 (en)	2025-03-06
DK2187882T3 (da)	2013-04-08
JP2014062118A (ja)	2014-04-10
CA2693697A1 (en)	2009-01-15
US9314452B2 (en)	2016-04-19
CN101848712A (zh)	2010-09-29
CA2693697C (en)	2017-07-25
US8338453B2 (en)	2012-12-25
US20200093805A1 (en)	2020-03-26
US20130217718A1 (en)	2013-08-22
US20170014390A1 (en)	2017-01-19
JP2010533193A (ja)	2010-10-21
HRP20130057T1 (hr)	2013-02-28
BRPI0814624A2 (pt)	2015-01-27
US11083713B2 (en)	2021-08-10
CN101848712B (zh)	2013-07-24
US20140171463A1 (en)	2014-06-19
US20090062330A1 (en)	2009-03-05
JP5468001B2 (ja)	2014-04-09
US20170020851A1 (en)	2017-01-26
PT2187882E (pt)	2013-04-17
US20220168283A1 (en)	2022-06-02
CA2970273A1 (en)	2009-01-15

Publication	Publication Date	Title
PL2187882T3 (pl)	2013-05-31	Leczenie postępującej choroby neurodegeneracyjnej ibudilastem
SI2205245T1 (sl)	2015-10-30	Terapevtska uporaba diaminofenotiazinov
GB0813740D0 (en)	2008-09-03	Therapeutic compounds
GB2464440B (en)	2012-04-11	Massager
GB0806794D0 (en)	2008-05-14	Therapeutic compounds
GB0804755D0 (en)	2008-04-16	Therapeutic compounds
GB0908193D0 (en)	2009-06-24	Treatment of disease state
ZA201202346B (en)	2015-11-25	Therapeutic agent for mood disorders
GB0700972D0 (en)	2007-02-28	Treatment of inflammatory disease
GB0715790D0 (en)	2007-09-26	Drug combination for the treatment of sialorrhoea
GB0720976D0 (en)	2007-12-05	Treatment of inflammatory disease
GB0809476D0 (en)	2008-07-02	Treatment of neurodegenerative disorders
GB0723100D0 (en)	2008-01-02	Treatment of HFnEF
GB0702862D0 (en)	2007-03-28	Therapeutic compounds
EP2212701A4 (en)	2011-10-05	NEW TREATMENT OF AUTOIMMUNE DISEASES
GB0906026D0 (en)	2009-05-20	Therapeutic compounds
GB0708186D0 (en)	2007-06-06	Therapeutic compounds
GB0817859D0 (en)	2008-11-05	Treatment of proteostatic disease
GB0819543D0 (en)	2008-12-03	Treatment of proteostatic disease
GB0701350D0 (en)	2007-03-07	Therapeutic invention
GB0919113D0 (en)	2009-12-16	Therapeutic invention
GB0908666D0 (en)	2009-07-01	Treatment of proteostatic disease
GB0907254D0 (en)	2009-06-10	Combating disease
GB0810952D0 (en)	2008-07-23	Therapeutic substances
GB0812816D0 (en)	2008-08-20	Therapeutic substances